AI FOR MELANOMA
Helping more people survive skin cancerEvery
someone is diagnosed with melanoma
Every
someone dies from melanoma
Caught early
%
of melanoma is survivable
Working to make melanoma deaths a thing of the past
Our ambition is to help more people survive skin cancer
We can do that by using our proprietary AI technology to improve access to high quality skin cancer screening.
Watch Neil explain how we think about melanoma and where we think we can help.
Awards
Our Blogs
Skin Analytics response to BMJ article: B2C apps not up to standard… SA’s evidence much stronger.
In February 2020, skin cancer researchers released a paper calling into question the quality of evidence behind the current crop of consumer-facing skin cancer apps. Given that we’re focused on the integration of our AI into health providers like the NHS and Vitality Health, we weren’t part of this paper. The conclusion was that the studies were poorly designed and didn’t validate the claims the companies are making about their products.
The paper was published in the BMJ and is a stark reminder that machine learning applied to healthcare requires high quality clinical evidence. That lesson was shared with me by one of the authors of the paper way back in 2013. It has been a key pillar of our strategy at Skin Analytics ever since.
New data shows DERM, our AI skin cancer diagnosis tool, could be as accurate as clinical specialist
The prospective, diagnostic trial saw DERM, our AI platform, correctly identify all malignant lesions (100% sensitivity) with an average AUROC of 95.8% with 65% specificity versus 70% specificity and a 77% AUROC score demonstrated by the clinical experts. DERM, a CE marked medical device, was developed as a tool to aid clinicians in identifying 11 common skin lesion types, including melanoma.